Sugi Predict

Sugi Predict / Compounds / SCHEMBL5509672

SCHEMBL5509672

SCHEMBL5509672

CCOC(=O)C1(C)CN(C(=O)OC(C)(C)C)CC1=O

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 2/20 0.41
▸ ADORA1 P30542 1/20 0.39
▸ DDB1 Q16531 4/20 0.37
▸ CRBN Q96SW2 4/20 0.37
▸ ALOX15 P16050 1/20 0.36
▸ USP2 O75604 1/20 0.35
▸ SMN1; SMN2 Q16637 1/20 0.35
▸ GLA P06280 2/20 0.33
▸ KMT2A Q03164 1/20 0.33
▸ L3MBTL1 Q9Y468 1/20 0.33
▸ ESR2 Q92731 1/20 0.33
▸ POLB P06746 1/20 0.33
▸ KDM4E B2RXH2 1/20 0.32
▸ ALDH1A1 P00352 1/20 0.32
▸ HPGD P15428 1/20 0.32
▸ RECQL P46063 1/20 0.32
▸ HSD17B10 Q99714 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18618412 0.87 ADORA1 (0.42) NR1H2ADORA1DDB1CRBNALOX15
SCHEMBL29450194 0.87 ADORA1 (0.42) NR1H2ADORA1DDB1CRBNALOX15
SCHEMBL13047175 0.87 ADORA1 (0.42) NR1H2ADORA1DDB1CRBNALOX15
SCHEMBL28797751 0.81 NR1H2 (0.45) NR1H2ADORA1DDB1CRBNUSP2
SCHEMBL27168333 0.81 ALOX15 (0.40) ALOX15SMN1; SMN2KMT2AL3MBTL1POLB
SCHEMBL14701441 0.81 ADORA1 (0.40) NR1H2ADORA1DDB1CRBNALOX15
SCHEMBL20411109 0.79 NR1H2 (0.36) NR1H2ADORA1DDB1CRBNKMT2A
SCHEMBL2377172 0.78 DDB1 (0.42) ADORA1DDB1CRBNALOX15USP2
SCHEMBL22118733 0.78 ADORA1 (0.35) NR1H2ADORA1DDB1CRBNUSP2
SCHEMBL31504609 0.77 ALOX15 (0.41) ALOX15SMN1; SMN2KMT2AL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4013749-B1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS INC (US) 2026-03-11 — — EP disclosed
US-20260049063-A1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS INC (US) 2026-02-19 — — US disclosed
US-12435046-B2 Alkynyl quinazoline compounds BLACK DIAMOND THERAPEUTICS, INC. (US) 2025-10-07 — — US disclosed
CN-114945571-B Cyclic compounds and methods of use thereof 薛定谔公司 2025-02-25 — — CN disclosed
US-20240254143-A1 OREXIN RECEPTOR AGONISTS AND USES THEREOF APTUIT (VERONA) SRL (IT) 2024-08-01 — — US disclosed
CN-117616030-A Orexin receptor agonists and uses thereof 爵士制药爱尔兰有限公司 2024-02-27 — — CN disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 — — US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 — — US disclosed
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRÖDINGER, INC. 2024-01-18 — — US disclosed
EP-3571198-B1 BICYCLIC AMINES AS JAK KINASE INHIBITORS LEO PHARMA AS (DK) 2023-02-01 — — EP disclosed
EP-4013749-A1 ALKYNYL QUINAZOLINE COMPOUNDS Black Diamond Therapeutics, Inc. (US) 2022-06-22 — — EP disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 — — WO disclosed
WO-2021134004-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME SCHRODINGER, INC. (US) 2021-07-01 — — WO disclosed
WO-2021030711-A1 ALKYNYL QUINAZOLINE COMPOUNDS BLACK DIAMOND THERAPEUTICS, INC. (US) 2021-02-18 — — WO disclosed
US-10851116-B2 Bicyclic amines as novel JAK kinase inhibitors LEO PHARMA A/S (DK) 2020-12-01 — — US disclosed
US-10851116-B2 Bicyclic amines as novel JAK kinase inhibitors LEO PHARMA A/S (DK) 2020-12-01 — — US disclosed
WO-2018134352-A1 BICYCLIC AMINES AS NOVEL JAK KINASE INHIBITORS LEO PHARMA A/S (DK) 2018-07-26 — — WO disclosed
EP-1838702-A1 PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS Pfizer Products Inc. (US) 2007-10-03 — — EP disclosed
US-20060183763-A1 Novel pyrrolidyl derivatives of heteroaromatic compounds PFIZER INC 2006-08-17 — — US disclosed
WO-2006070284-A1 PYRROLIDYL DERIVATIVES OF HETEROAROMATIC COMPOUNDS AS PHOSPHODIESTERASE INHIBITORS PFIZER PRODUCTS INC. (US) 2006-07-06 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12435046-B2 Alkynyl quinazoline compounds GLS, GLS2, MCL1 NR1H2 1398/4885ADORA1 3180/4885DDB1 601/4885
US-20060183763-A1 Novel pyrrolidyl derivatives of heteroaromatic compounds PDE12, PDE4A, PDE7A NR1H2 4053/4885ADORA1 1496/4885DDB1 1632/4885
US-10851116-B2 Bicyclic amines as novel JAK kinase inhibitors JAK1, JAK2, JAK3 NR1H2 2452/4885ADORA1 697/4885DDB1 3016/4885
US-20260049063-A1 ALKYNYL QUINAZOLINE COMPOUNDS H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, MCL1, BCL6 NR1H2 1002/4885ADORA1 1156/4885DDB1 2278/4885
US-20240018157-A1 CYCLIC COMPOUNDS AND METHODS OF USING SAME MALT1, FKBP1B, FKBP1A NR1H2 1989/4885ADORA1 3356/4885DDB1 1251/4885
US-20240254143-A1 OREXIN RECEPTOR AGONISTS AND USES THEREOF HCRTR1, HCRTR2, NPY1R NR1H2 108/4885ADORA1 63/4885DDB1 4852/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.